Genio (neuromodulator for the treatment of sleep anoe)

History

2025: Market Entry

In early August 2024, Nyxoah, based in Mont Saint-Gibert (Belgium), announced the release of the Genio system for the treatment of obstructive sleep apnea. The solution provides for the use of a module attached to the neck.

Obstructive sleep apnea syndrome (SOAS) is a common pathology characterized by the occurrence of repeated episodes of sleep cessation of breathing. This is due to a temporary decline in the soft tissues of the upper respiratory tract, which leads to their complete overlap. The disease occurs in men and women of all ages. At the same time, the SOAS does not pose a direct threat to human life. During respiratory arrest, the concentration of oxygen in the blood drops and the amount of carbon dioxide increases. After reaching a critical level, the center located in the medulla oblongata is stimulated, leading to a resumption of breathing.

𝓲

Фото: nyxoah.com

The Genio system uses a special electrode near the sublingual nerve, which stimulates tissues by keeping the airways open. The device receives power from an external source attached to the neck. The accompanying mobile application for the smartphone allows you to track the quality and duration of sleep, as well as adjust the stimulation parameters.

Genio is the world's first unique, wirelessly designed neuromodulator designed to meet the needs of patients. By stimulating the sublingual nerve on both sides, Genio maintains upper airway patency during sleep, Nyxoah notes.

The Genio product has received approval from the U.S. Food and Drug Administration (FDA). The system is claimed to be highly effective regardless of the patient's position during sleep. The novelty significantly improves the quality of night rest.^[1]

Notes